Seeking Alpha

seelisa

seelisa
Send Message
View as an RSS Feed
View seelisa's Comments BY TICKER:
Latest  |  Highest rated
  • An Early Valuation Of Neuralstem's NSI-189 For MDD [View article]
    Well - I am hoping to like it in the future with this new drug. We'll see. As for liking it right now, only in the most serious cases and then with the recognition that modern treatment can be lifesaving for such acuity. To generalize beyond that to my entire practice is an emotional projection on your part, an interpretation of our discussion here in which you have drawn an erroneous conclusion with no real supportive data.
    Jun 29 09:40 AM | Likes Like |Link to Comment
  • An Early Valuation Of Neuralstem's NSI-189 For MDD [View article]
    "The good thing here with CUR is that is reverses some of the damage to the brain-hippocampus- caused by the anti depressants. " We don't know if NSI-189 can reverse hippocampal damage yet. And while the current treatment selection of AD's for depression isn't the greatest, one positive is that SSRI treatment does appear to preserve hippocampal volume. Recurrent depressive episodes are shown to damage that area and (perhaps due to their anti-inflammatory effect) SSRI treatment is proving out to preserve the hippocampus from volume loss secondary to depression for chronic sufferers. Stimulation of neurogenesis is what makes antidepressant therapy efficacious. Just want to respond to your untrue statement that AD's cause such damage. Chronic depression causes such damage and AD treatment of chronic depression is proving to protect the brain from literal shrinking. But it takes a long time. A hope for NSI-189 in humans is that it will prove to be more targeted in this protective action for the hypothalamus and will preserve and restore much more quickly than current options.
    http://bit.ly/1iQ9iuZ
    http://preview.tinyurl...
    http://1.usa.gov/1iQ9iv1
    Jun 28 09:31 PM | 1 Like Like |Link to Comment
  • Neuralstem NSI-189 Abstract Teases At Potential Greatness [View article]
    Their press releases can be counted. There were two releases announcing conferences and 2 announcing results this past month. You believe they 'milked', with 'multiple announcements of the same results'. That appears to be an exaggerated statement. They have planned on a ph2 for a prolonged period, making statements about their commitment to a phase 2 as long as a year ago, repeated consistently through their June conference. Yet you make this statement "We have been told NSI-189 was going to be sold OR the company might proceed on their own." They have not changed their narrative and your statement indicates lack of understanding or just lack of dd. These are not emotionally based points, they are just information based from CUR statements. Your post referred to trust/'getting a sense' followed by projected application of motivation evidenced by statement management may be 'milking' with repeated prs. Those are emotionally based sentiments and prove to be not based on the information the company has provided. Perhaps you are referring to statements made by other investors? Management did not state that they were looking to make a deal with NSI-189 this June. They have been consistent in verbalizing plan to carry out ph2 and staying open to partnership talks, but they did not make a statement of desire to sell prior to ph2. If you read this post, you will hopefully see that I am not asking you to agree. I am not trying to convince you of anything except the difference between a statement based on emotion vs an information based statement. Nothing wrong with selling, ever. But you have twice used faulty info to support your decision, and my responses are constructed to clarify with information given by the company, which can be verified simply by going to the company site.
    Jun 28 12:57 PM | Likes Like |Link to Comment
  • An Early Valuation Of Neuralstem's NSI-189 For MDD [View article]
    Or do the numbers increase because the mental health system has been dismantled and there is no system of ongoing care and assistance for them, resulting in higher need for acute episodic treatment?
    Jun 28 12:17 PM | 1 Like Like |Link to Comment
  • An Early Valuation Of Neuralstem's NSI-189 For MDD [View article]
    Hopefully. We'll see. There were side effects common to psychopharm drugs. We don't know enough yet. And the current AD generation are highly anti-inflammatory - not a bad thing - and that may be what causes efficacy for those client responders - thus their 'better living thru chemistry' may be decreasing destructive inflammation in their brains...Either way - both Prozac and NSI-189 may be 'better living thru chemistry', though we have no evidence that one form of chemistry is 'better' than the other at this time.
    Jun 27 11:02 AM | Likes Like |Link to Comment
  • An Early Valuation Of Neuralstem's NSI-189 For MDD [View article]
    Ditto.
    Jun 27 10:50 AM | Likes Like |Link to Comment
  • Neuralstem NSI-189 Abstract Teases At Potential Greatness [View article]
    Fibonacci - Fig 2 is pre and post dose of day 28 for treated and placebo. Predose image likely reflects treatment effect of treated group for the 27 days prior. Both pre and post images were day 28, as opposed to day zero baseline pic and day 28 treatment group/placebo group pic.
    Jun 26 02:07 PM | Likes Like |Link to Comment
  • An Early Valuation Of Neuralstem's NSI-189 For MDD [View article]
    Side effects is a term helpful in assessing drug tolerability. For a drug to be efficacious, if has to meet criteria of significance in predefined endpoint goals. Side effects are separate from efficacy - or - target effect. Side effects not part of overall response to drug, hopefully they don't exceed placebo and are not common user experience where intended drug effect are common user experience. Side effects are a safety and tolerability monitoring duty of patient and clinician, as opposed to a drug marketing concept by big pharma. If it were up to be pharma, listing of side effects would be omitted from every drug label. Such listing isn't exactly something big pharmas marketing depts would volunteer for.
    Jun 26 01:52 PM | Likes Like |Link to Comment
  • An Early Valuation Of Neuralstem's NSI-189 For MDD [View article]
    This is a new psychopharmacological novel molecule. Lots of chemistry involved in the creation of this treatment.
    Jun 26 01:42 PM | 1 Like Like |Link to Comment
  • An Early Valuation Of Neuralstem's NSI-189 For MDD [View article]
    It's novel molecule, novel mechanism of action, just finished ph1 trial. It's ALL new.
    Jun 26 01:40 PM | Likes Like |Link to Comment
  • Neuralstem NSI-189 Abstract Teases At Potential Greatness [View article]
    Crickets coming out of both? They were academic presentations - and were received quite well. It was an excellent little study. It is not unusual for a presentation to get some press, especially when results are encouraging. 2 presentations will get that much more attention. The presentations, both given at respected research conferences, don't reflect any negative management agenda. The presenters were researchers. The results were nicely supportive of further study. There's been a little buzz since but only 2 press releases from the company after presentations completed, and 2 announcing presentations. No evidence of heavy pumping there. It was just a ph1. Nothing earth shattering is likely to occur this early, but things are looking good so far.
    The company has said they were planning the NSI-189 ph2 for a very long time now. There is no story change related to this ph2. The company has maintained the same narrative for the past year. Were you expecting them to unload it for ph2? They've had that trial planned and a recruitment population agreement in place for since 2013. Would be quite disappointing to see them sell before the ph2. The molecule will be in a position of greater worth after the next trial.
    None of us like to see dilution, or threat of. But in a rapidly maturing biotech it is generally unavoidable. Perhaps more important than the existence of a shelf offering is the existence of financial transparency of the company. If transparency is lacking, increased caution and skepticism is called for. CUR financials are quite transparent and the money trail is easily followed. So you don't have to worry about trust - you can instead assess the evidence, look at the financial documents. Once you've done that, you are likely to see that their financial management is good.
    So - you intuited warning signs. One, your mention of NSI-189, was based on your own lack of information about the company plans. Faulty dd.
    Another - your 'crickets' reference - may indicate a lack of appropriate expectations regarding release of ph1 trial news. Ph1 is just the beginning and release of ph1 results are very rarely a cause for a big press reaction. This ph1 received more attention than most. It caused a fairly impressive response for such an early phase study. So perhaps your frustration is related to having had expectations inappropriate of the stage of study.
    Jun 26 01:32 PM | Likes Like |Link to Comment
  • Cynapsus Offers Potential Big Returns [View article]
    Audioblog from Michael J. Fox foundation re off episodes.

    http://bit.ly/1jzRRth
    Jun 18 09:36 PM | Likes Like |Link to Comment
  • Cynapsus Offers Potential Big Returns [View article]
    The advantage of the inhaled Levadopa is its short time of action and excretion. Bulk is excreted . It is not raising overall blood levels of L-dopa in any consistent way, beyond an hour, and therefore likely doesn't increase dyskinesia risk.
    Jun 15 12:15 PM | Likes Like |Link to Comment
  • Cynapsus Offers Potential Big Returns [View article]
    The treatment you link to is also an off-episode treatment. Interesting study - they treated their off episodes successfully but the trial required participants to engage in one month of continued use (which is likely what CYNAF will need to do in their upcoming study also). Relief started in 10 minutes and lasted for an hour - which is just about how long current injectable form of apomorphine lasts. Would need to look at this study closely to see how efficacy compares to current apo - but if it comes close at all, it would surely be preferred over an injection. CYNAF sublingual appears to have effect for a little more than 2 hours, double the time of this inhaled levadopa. But we'll need to see more use in Parkinson's patients before that is proven as consistent. Both agents are worth a watch. When CYNAF develops apl-130277 a little more, efficacy comparison using UPDRS III will give more info as to how both agents compare in efficacy.
    Thank you for bringing Civitas to my attention. I am intrigued and will try to dig up the write-up of their recent 2b so I can read safety, tolerability, efficacy etc...in greater detail.
    Jun 14 01:43 PM | 3 Likes Like |Link to Comment
  • Cynapsus Offers Potential Big Returns [View article]
    Uhmm...you forgot to find out what CYNAF medication is and does before you wrote your response...Your response has nothing to do with this article or this company or this medication or its population...
    Jun 13 02:08 PM | 1 Like Like |Link to Comment
COMMENTS STATS
192 Comments
257 Likes